Thus, the PerELISA population is not representative from the general population, yet most patients (i.e., ∼70%) with HER2-positive/hormone receptor-positive breast cancer in PerELISA had endocrine sensitivity tumours. The gene discussed is ERBB2; the disease is neoplasm.